INDV News & Events

Indivior announced that it has entered into a $175M accelerated share repurchase agreement with Barclays. The ASR will be executed under Indivior's existing $400M share repurchase program previously authorized by the company's board of directors. Under the ASR agreement, Indivior will make an upfront payment of $175M to Barclays and expects to receive an initial delivery of 3,717,473 shares promptly following execution. The final number of shares repurchased will be determined based on the volume weighted average price of Indivior's common stock during the term of the ASR, less a discount. Final settlement is expected to occur no later than the end of June. Indivior does not expect the ASR to impact its previously issued financial guidance. The remaining $100M under the share repurchase authorization may be used for additional repurchases from time to time, subject to market conditions and other factors. Repurchases may be made through open market transactions, privately negotiated transactions, or other methods permitted under applicable law.

Consensus $1.16B. Raises FY26 adjusted EBITDA view to $620M-$660M from $535M-$575M. Backs FY26 operating expenses view $430M-$450M. "Strong SUBLOCADE performance in the first quarter led us to raise our 2026 financial guidance," said Ryan Preblick, Chief Financial Officer. "We now expect 2026 total SUBLOCADE net revenue growth of 13% year-over-year and adjusted EBITDA growth of 50% year-over-year at the midpoint of our guidance ranges. We strengthened our financial position with the completion of a $500 million convertible senior notes offering and returned capital to our shareholders through the opportunistic repurchase of $125 million in shares during the quarter. We are committed to creating long-term shareholder value as we advance the Indivior Action Agenda."

Reports Q1 revenue $317M, consensus $272.84M. "We are encouraged by our first quarter results, which reflect the progress we are making against Phase II of the Indivior Action Agenda - Accelerate," said Joe Ciaffoni, Chief Executive Officer. "Year-over-year we accelerated SUBLOCADE net revenue and dispense unit growth and grew adjusted EBITDA and cash at an even faster rate while executing on our capital deployment strategy. We remain focused on accelerating SUBLOCADE dispense unit growth, growing our bottom line at a significantly faster rate, and strategically deploying capital as we earn our way to Phase III of the Indivior Action Agenda - Breakout - which we are on track to enter in the second half of 2026."

Indivior Pharmaceuticals will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine Annual Conference, held April 23-26, 2026, in San Diego, California. The data add to the growing body of evidence evaluating extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE, in supporting meaningful outcomes for people living with OUD, including overdose-related outcomes and broader indicators associated with recovery. Impact of OAT in individuals with OUD who experienced an overdose in Ontario, Canada: This retrospective nested case-control study used Ontario administrative health data of more than 45,000 patients with OUD to evaluate associations between MOUD treatments, including SUBLOCADE, transmucosal buprenorphine, methadone, and sustained-release oral morphine and the risk of opioid-related fatal and non-fatal overdose. Most overdose events occurred off treatment: Patients with higher MOUD coverage experienced less non-fatal and fatal overdose compared to those with lower MOUD coverage. Buprenorphine-based MOUD significantly reduced overdose risk: Of all MOUD, SUBLOCADE accounted for the smallest proportion of non-fatal and fatal OD events compared to no treatment. Both SUBLOCADE and TM-BUP had the lowest odds of all MOUD odds of non-fatal and fatal overdose versus no MOUD. Study limitations include potential misclassification in administrative data, incomplete or inaccurate capture of opioid-related OD events and OAT use, and absence of a direct measure of OAT adherence. Associations between remission from opioid use disorder and treatment-relevant outcomes: Provisional findings from the Remission from OUD as a Treatment Endpoint followed 443 participants within 0-3 months of starting treatment with SUBLOCADE for up to 12 months to understand how OUD remission relates to treatment-relevant and recovery-related outcomes. Remission as an indicator of improved outcomes: Individuals entering the study in remission for 3-months indicated lower craving, lower withdrawal, lower pain, better quality of life, and lower rates of unemployment than those not in remission. Complete abstinence may neither be sufficient nor necessary: Opioid misuse and OUD remission are not always consistent; an individual may abstain from opioid misuse while not yet meeting criteria for 3-month remission, underscoring the importance of remission as a clinically meaningful treatment endpoint. One study limitation is that participants entered at varying BUP-XR treatment durations, so study entry does not align with treatment initiation.